Takeda news
TAK-438 Enters Phase II Clinical Trialsfor the Treatment of Reflux Esophagitis
Osaka, Japan, November 18, 2009 - Takeda Pharmaceutical Company Limited (“Takeda”) announced that TAK-438, which is the drug for acid-related diseases, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.
- Takeda Well-Being Program 2009 –"Giving Children in Long-term Treatment the Energy to Live"
Osaka, Japan, November 18, 2009 - Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has decided to start the Takeda Well-Being Program 2009 - "Giving Children in Long-term Treatment the Energy to Live" (hereinafter referred to as the "Program").
Takeda Selected for Carbon Disclosure Leadership Index 2009
November 13, 2009, Osaka, Japan – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today that it has received the honor of being selected for the Carbon Disclosure Leadership Index (CDLI) 2009 as one of the companies in Japan which have taken the most advanced approaches to emissions disclosure.
Blister card for Benet® 17.5 mg tablets for the treatment of osteoporosis receivesthe Good Design Award 2009 and the Japan Packaging Contest Appropriate Packaging Award
Osaka, Japan, October 23, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today that it has received the Good Design Award 2009[*1] from the Japan Industrial Design Promotion Organization for the blister card packaging for Benet® 17.5 mg tablets, which is indicated for the treatment of osteoporosis.
Takeda Announces Principal Sponsorship of the Yokohama Women's Marathon
Osaka, Japan, October 20, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today its principal sponsorship of the inaugural Yokohama Women's Marathon, which will be held on Sunday, November 15, 2009.
Takeda to Establish Four Sales and Marketing Subsidiaries toExpand its Operations in Mexico, Turkey and Five Other Countries in Europe
Osaka, Japan, October 1, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries – Takeda Pharmaceuticals Mexico, S.A.
- Login or register to post comments
- Read more
- 63 reads
- Feed: Takeda Pharmaceutical Company Limited
- Original article
Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
Osaka and Tokyo, Japan, October 1, 2009 --- Takeda Pharmaceutical Company Limited (Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Osaka, President and CEO: Masahiro Kato), Mitsubishi Tanabe Pharma Corporation (Osaka; President and CEO: Michihiro Tsuchiya), and Eisai Co., Ltd.
- Login or register to post comments
- Read more
- 106 reads
- Feed: Takeda Pharmaceutical Company Limited
- Original article
